Advertisement
Essay

Essay Essays are opinion pieces on a topic of broad interest to a general medical audience.

See all article types »

Regulation of Clinical Research Sponsored by Pharmaceutical Companies: A Proposal

  • Julio Sotelo
  • Published: July 11, 2006
  • DOI: 10.1371/journal.pmed.0030306

Reader Comments (4)

Post a new comment on this article

Laudable, But Will Fall Short Of Expectations

Posted by plosmedicine on 30 Mar 2009 at 23:58 GMT

Author: Ajai Singh
Position: Editor
Institution: Mens Sana Monographs
E-mail: mensanamonographs@yahoo.co.uk
Submitted Date: August 17, 2006
Published Date: August 18, 2006
This comment was originally posted as a “Reader Response” on the publication date indicated above. All Reader Responses are now available as comments.

The effort is in the right direction, but there are many problems with this proposal. Let me list a couple:

1. How is one to ensure that the 'Collegiate Research Council (CRC)' itself is not liable to manipulation by pharma?

2. How is one to further ensure that every proposal invariably passes through this CRC? Will this body have statutory powers? Who will give it such powers? If not, what is to prevent pharma from bypassing this body, getting pliant researchers to work for them anyway, and pump in dollars to hype it all up? Even carry out a hush hush campaign to descredit CRC itself?

A classic example of the best of intentions not getting the best of results.

The attempt is laudable, but will fall short of expectations unless more spade work is done, and greater teeth given to the proposal.

I hope the author concerned works over the various ramifications of the proposal, and other like minded join in the effort.

Moreover, the attempt should not be to tarnish all of pharma. That would be imbecile and counterproductive. Rather it should be to make it really difficult for the unscrupulous to make hay, whether they be in industry, or academia.

No competing interests declared.